Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P85Z | ISIN: US67080M1036 | Ticker-Symbol:
NASDAQ
06.06.25 | 17:01
12,820 US-Dollar
+2,40 % +0,300
1-Jahres-Chart
NURIX THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
NURIX THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur NURIX THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiStifel-Analysten bekräftigen Kaufempfehlung für Nurix-Aktie nach SNY-Deal2
DiStifel analysts maintain Buy rating on Nurix stock after SNY deal3
MoLeerink Partners maintains market perform rating on Nurix stock3
NURIX THERAPEUTICS Aktie jetzt für 0€ handeln
MoSanofi pays $15M for another STAT6 degrader from fruitful Nurix collab7
MoSanofi extends license option with Nurix's STAT6 program3
MoSanofi verlängert Lizenzoptionsvertrag mit Nurix' STAT6-Programm8
MoNurix secures additional $15 million from Sanofi license deal2
MoNurix Therapeutics, Inc.: Sanofi Exercises License Extension Option to Nurix's STAT6 Program103STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi...
► Artikel lesen
19.05.Nurix Therapeutics, Inc. - 8-K, Current Report1
16.05.Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)168SAN FRANCISCO, May 16, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted...
► Artikel lesen
28.04.Nurix Therapeutics, Inc.: Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs2
25.04.Nurix Therapeutics reports breakthroughs in cancer drug research1
25.04.Nurix Therapeutics meldet Durchbrüche in der Krebsmedikamentenforschung1
25.04.Nurix Therapeutics, Inc.: Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets1
17.04.Nurix gets FDA clearance to initiate trial for its anti-inflammatory drug candidate3
17.04.Nurix Therapeutics, Inc.: Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions230Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical...
► Artikel lesen
11.04.Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)201SAN FRANCISCO, April 11, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
► Artikel lesen
10.04.UBS cuts Nurix stock price target to $30, maintains Buy rating2
09.04.Nurix stock target cut to $35 at Stifel, maintains Buy rating1
09.04.Stephens cuts Nurix stock price target to $30, maintains Overweight2
Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1